$CTIC double corrected Pr $2.17 called 1/4/14
Post# of 74
Posted On: 12/04/2014 7:52:20 AM
$CTIC double corrected Pr $2.17
called 1/4/14 $2.20
Website
Shares Outstanding: 145.14M
Float: 121.57M
% Held by Insiders: 16.77%
% Held by Institutions: 28.90%
Shares Short (as of May 15, 2014): 13.91M
Short Ratio (as of May 15, 2014): 5.80
Short % of Float (as of May 15, 2014): 11.20%
Shares Short (prior month): 13.24M
Recent Trades
Headlines[/b
Thursday, December 4, 2014
2:23 am CTI BioPharma receives $15 mln milestone payment for TRISENOXBriefing.com (Thu 2:23AM EST)
CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®PR Newswire (Thu 1:30AM EST)
Tuesday, December 2, 2014
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Offat TheStreet (
Monday, December 1, 2014
CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual MeetingPR Newswire
Wednesday, November 26, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online
Monday, November 17, 2014
CTI BioPharma to Present at the Upcoming Investor ConferencesPR Newswire
Thursday, November 13, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights ofEDGAR Online
Friday, November 7, 2014
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred StockPR Newswire [
Thursday, November 6, 2014
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred StockPR Newswire
CTI BIOPHARMA CORP Files SEC form 8-K/A, Financial Statements and ExhibitsEDGAR Online
CTI BIOPHARMA CORP FinancialsEDGAR Online Financials
Monday, November 3, 2014
10-Q for CTI BioPharma Corp.Company Spotlight
Friday, October 31, 2014
CTI BIOPHARMA CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online
Thursday, October 30, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online (
Wednesday, October 29, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online
CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET todayCCBN
CTI BioPharma Reports Third Quarter 2014 Financial ResultsPR Newswire
Q3 2014 CTi Biopharma Corp Earnings Release - After Market CloseCCBN
Monday, October 27, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or DispoEDGAR Online
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer TherapyPR
called 1/4/14 $2.20
Website
Shares Outstanding: 145.14M
Float: 121.57M
% Held by Insiders: 16.77%
% Held by Institutions: 28.90%
Shares Short (as of May 15, 2014): 13.91M
Short Ratio (as of May 15, 2014): 5.80
Short % of Float (as of May 15, 2014): 11.20%
Shares Short (prior month): 13.24M
Recent Trades
Headlines[/b
Thursday, December 4, 2014
2:23 am CTI BioPharma receives $15 mln milestone payment for TRISENOXBriefing.com (Thu 2:23AM EST)
CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®PR Newswire (Thu 1:30AM EST)
Tuesday, December 2, 2014
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Offat TheStreet (
Monday, December 1, 2014
CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual MeetingPR Newswire
Wednesday, November 26, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online
Monday, November 17, 2014
CTI BioPharma to Present at the Upcoming Investor ConferencesPR Newswire
Thursday, November 13, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights ofEDGAR Online
Friday, November 7, 2014
CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred StockPR Newswire [
Thursday, November 6, 2014
CTI BioPharma Announces Proposed Public Offering of Convertible Preferred StockPR Newswire
CTI BIOPHARMA CORP Files SEC form 8-K/A, Financial Statements and ExhibitsEDGAR Online
CTI BIOPHARMA CORP FinancialsEDGAR Online Financials
Monday, November 3, 2014
10-Q for CTI BioPharma Corp.Company Spotlight
Friday, October 31, 2014
CTI BIOPHARMA CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online
Thursday, October 30, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online (
Wednesday, October 29, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanEDGAR Online
CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET todayCCBN
CTI BioPharma Reports Third Quarter 2014 Financial ResultsPR Newswire
Q3 2014 CTi Biopharma Corp Earnings Release - After Market CloseCCBN
Monday, October 27, 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or DispoEDGAR Online
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer TherapyPR
(0)
(0)